Sub Banner Image

Sarepta Shares Fall After EU Regulator Rejects Gene Therapy

Markets

Naomi Kresge, Gerry Smith

·

July 25, 2025

·

Bloomberg

Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment in the US.

More from

Bloomberg

More

Markets

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.